Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:03:27.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a significant update in the study details related to the safety and efficacy of Pembrolizumab in combination with investigational agents for the treatment of extensive-stage small cell lung cancer in need of second-line therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:46:22.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying health conditions and prior treatments required for inclusion in the study. This change provides more comprehensive information about the requirements for potential participants in the clinical trial.
    Difference
    38%
    Check dated 2024-05-22T21:34:40.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:32:18.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.